GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Shanghai Pharmaceuticals Holding Co Ltd (OTCPK:SHPMF) » Definitions » Other Net Income (Loss)

SHPMF (Shanghai Pharmaceuticals Holding Co) Other Net Income (Loss) : $0 Mil (TTM As of Sep. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Shanghai Pharmaceuticals Holding Co Other Net Income (Loss)?

Shanghai Pharmaceuticals Holding Co's Other Net Income (Loss) for the three months ended in Sep. 2024 was $-0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Sep. 2024 was $0 Mil.

Shanghai Pharmaceuticals Holding Co's quarterly Other Net Income (Loss) increased from Mar. 2024 ($0 Mil) to Jun. 2024 ($0 Mil) but then declined from Jun. 2024 ($0 Mil) to Sep. 2024 ($-0 Mil).

Shanghai Pharmaceuticals Holding Co's annual Other Net Income (Loss) stayed the same from Dec. 2021 ($0 Mil) to Dec. 2022 ($0 Mil) but then declined from Dec. 2022 ($0 Mil) to Dec. 2023 ($-0 Mil).


Shanghai Pharmaceuticals Holding Co Other Net Income (Loss) Historical Data

The historical data trend for Shanghai Pharmaceuticals Holding Co's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Pharmaceuticals Holding Co Other Net Income (Loss) Chart

Shanghai Pharmaceuticals Holding Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Net Income (Loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Shanghai Pharmaceuticals Holding Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Other Net Income (Loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Shanghai Pharmaceuticals Holding Co Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Pharmaceuticals Holding Co Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Shanghai Pharmaceuticals Holding Co's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Pharmaceuticals Holding Co Business Description

Address
No. 200 Taicang Road, Shanghai Pharmaceutical Building, Shanghai, CHN, 200020
Shanghai Pharmaceuticals is the second-largest medical distributor in China by revenue. It is vertically integrated and provides healthcare services in research and development, manufacturing, distribution, and retail. As of 2023, medical distribution is the largest segment, accounting for 89.8% of total revenue. It also has coverage of 31 provinces and cities nationwide.